Pediatric Nephrology

, Volume 4, Issue 6, pp 663–678 | Cite as

The ‘antiphospholipid syndrome’ and the ‘lupus anticoagulant’

  • J. Stewart Cameron
  • G. Frampton
Nephrology Review


In recent years an association has been described between, on the one hand, an in vitro prolongation of phospholipid-dependent coagulation tests (the ‘lupus anticoagulant’) or the demonstration of antiphospholipid antibodies and, on the other, clinical events, particularly recurrent thrombosis (usually venous but sometimes arterial), thrombocytopenia, and also recurrent mid-term fetal loss. Other less well-documented associations with haemolytic anaemia, livedo reticularis, strokes and other neurological syndromes have been suggested. The antibodies are present temporarily in many infections, are usually of IgM isotype and thrombosis does not occur. However, they are persistently present and mainly of IgG isotype in a number of auto-immune disorders associated with thrombosis, in particular systemic lupus erythematosus, in which 50% of patients will show antibody of one isotype or another. The strongest association is with antinuclear factor-negative lupus and ‘lupus-like’ disorders in which a full diagnosis of classical lupus cannot be made. The clotting test abnormality and antiphospholipid antibodies may be found also in otherwise normal individuals suffering thrombosis or fetal loss — the so-called primary antiphospholipid syndrome. These data raise important questions for management, but many details are controversial despite a decade's work; this review examines the present position and outlines some of the difficulties, particularly from the point of view of nephrology and paediatrics.

Key words

Antiphospholipid antibodies Lupus anticoagulant Recurrent thrombosis Thrombocytopenia Fetal loss Glomerular thrombi 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wasserman A, Neisser A, Bruck C (1906) Eine serologische Reaktion bei Syphilis. Dtsch Med Wochenschr 32:745–746Google Scholar
  2. 2.
    Pangborn MC (1941) A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 48:484–486Google Scholar
  3. 3.
    Gennerich W (1921) Über die Ätiologie des lupus erythematodes. Arch Syphil Dermatol 135:184–207Google Scholar
  4. 4.
    Moore JE, Lutz WB (1955) The natural history of lupus erythematosus: an approach to its study through chronic biologic false positive reactors. J Chron Dis 1:297–316Google Scholar
  5. 5.
    Conley CC, Hartmann RC (1952) A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 31:621–622Google Scholar
  6. 6.
    Feinstein DI, Rapaport SI (1972) Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1:75–95Google Scholar
  7. 7.
    Bowie WEJ, Thompson JH, Pascuzzi CA, Owen CA (1963) Thrombosis in systemic lupus erythematosus. J Clin Invest 62:416–430Google Scholar
  8. 8.
    Lechner K (1969) A new type of coagulation inhibitor. Thromb Diath Haemorrh 21:482–499Google Scholar
  9. 9.
    Schleider MA, Nachman RL, Jaffe EA, Coleman M (1976) A clinical study of the lupus anticoagulant. Blood 48:499–509Google Scholar
  10. 10.
    Johanssen EA, Lassus A (1955) The occurrence of circulating anticoagulants in patients with syphilis and biologic false positive antilipoidal antibodies. Blood 6:105–108Google Scholar
  11. 11.
    Laurell A-B, Nilsson IM (1957) Hypergammaglobulinemia, circulating anticoagulant and biologic false positive Wasserman reactions. J Lab Clin Med 49:694–707Google Scholar
  12. 12.
    Thiagarajan P, Shapiro SS, Marco L de (1980) Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity-mechanism of a lupus anticoagulant. J Clin Invest 66:397–405Google Scholar
  13. 13.
    Shapiro SS, Thiagarajan P (1982) Lupus anticoagulants. Prog Hemost Thromb 6:263–285Google Scholar
  14. 14.
    Mueh JR, Herbst KD, Rapaport SI (1980) Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 92:156–159Google Scholar
  15. 15.
    Williams H, Laurent R, Gibson T (1980) The lupus coagulation inhibitor and venous thrombosis: report of four cases. Clin Lab Haematol 2:139–144Google Scholar
  16. 16.
    Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV (1983) Thrombosis in SLE: striking association with the presence of circulating ‘lupus anticoagulant’. Br Med J 287:1021–1023Google Scholar
  17. 17.
    Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet II:1211–1214Google Scholar
  18. 18.
    Nilsson IM, Astedt B, Hedner V, Berezin D (1975) Intrauterine death and circulating anticoagulant (‘antithromboplastin’). Acta Med Scand 197:153–159Google Scholar
  19. 19.
    Firkin BG, Howard MA, Radford N (1980) Possible relationship between lupus inhibitor and recurrent abortions in young women. Lancet II:366Google Scholar
  20. 20.
    Soulier J-P, Boffa M-C (1980) Avortement a repetition, thrombose et anticaogulant circulant antithromboplastine. Nouv Presse Med 9: 859–864Google Scholar
  21. 21.
    Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Assche A van (1981) Arterial thrombosis, intrauterine death and lupus anticoagulant: detection of an inhibitor of prostacyclin formation. Lancet I:244–246Google Scholar
  22. 22.
    Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, Ferenc M (1985) Antibody to cardiolipin as a predictor of fetal distress or death. N Engl J Med 313:152–156Google Scholar
  23. 23.
    Derue GJ, Englert HJ, Harris EN, Hughes GRV (1985) Fetal loss in systemic lupus: association with anticardiolipin antibodies. J Obstet Gynaecol 5:207–209Google Scholar
  24. 24.
    Hughes GRV (1983) Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 287:1088–1089Google Scholar
  25. 25.
    Perico N, Pusinieri F, Remuzzi G (1984) The lupus anticoagulant. Proc Soc Exp Biol Med 176:337–341Google Scholar
  26. 26.
    Editorial (1984) Lupus anticoagulant. Lancet I:1157–1158Google Scholar
  27. 27.
    Feinstein DI (1985) Lupus anticoagulant, thrombosis and fetal loss. N Engl J Med 313:1348–1350Google Scholar
  28. 28.
    Editorial (1985) Anticardiolipin antibodies: a risk factor for thrombosis. Lancet I:912–913Google Scholar
  29. 29.
    Harris EN, Gharavi AE, Hughes GRV (1985) Antiphospholipid antibodies. Clin Rheum Dis 11:591–609Google Scholar
  30. 30.
    Hughes GRV, Harris EN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13:486–489Google Scholar
  31. 31.
    Harris EN (1987) Syndrome of the black swan. Br J Rheumatol 26: 324–326Google Scholar
  32. 32.
    Colaco CB, Elkon KB (1985) The lupus anticoagulant: a disease marker in anti nuclear antibody negative lupus that is cross reactive with autoantibodies to double stranded DNA. Arthritis Rheum 28: 68–74Google Scholar
  33. 33.
    Hughes GR, Asherson RA (1985) Atypical lupus with special reference to ANA negative lupus and lupus subsets. Adv Nephrol 14: 333–346Google Scholar
  34. 34.
    Meyer O, Piette J-C, Bourgeois P, Fallas P, Bletry O, Jungers P, Kahn M-F, Godeau P, Ryckwaert A (1987) Antiphospholipid antibodies: a disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosus (SLE). Comparison with a group of 91 patients with antinuclear antibody positive SLE. J Rheumatol 14:502–506Google Scholar
  35. 35.
    Frampton G, Cameron JS, Hartley RB (1987) Glomerular thrombi in lupus nephritis: an association with the presence of IgG anti-cardiolipin antibody (abstract). Nephrol Dial Transplant 2:424Google Scholar
  36. 36.
    Derksen RHMW, Bouma BN, Kater L (1987) The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus. Scand J Rheumatol 16:185–192Google Scholar
  37. 37.
    Sturfelt G, Nived O, Norberg R, Thorstensson R, Krook K (1987) Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 30:382–388Google Scholar
  38. 38.
    Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellmann D, Corash L (1987) The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin level. Ann Intern Med 106:524–531Google Scholar
  39. 39.
    Derksen RHMW, Haselaar P, Blokzijl L, Gmelig Meyling FHJ, Groot PG de (1988) Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 48:364–371Google Scholar
  40. 40.
    Hazeltine M, Rauch J, Danoff D (1988) Antiphospholipid antibodies in systemic lupus erythematosus: evidence of an association with positive Coombs' and hypocomplementemia. J Rheumatol 15: 80–86Google Scholar
  41. 41.
    Weidmann CE, Wallace DJ, Peter JB, Knight PJ, Bear MB, Klinenberg JR (1988) Studies of IgG IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol 15: 74–79Google Scholar
  42. 42.
    Kalunian KC, Peter JB, Middlekauff HR, Sayre J, Ando DG, Mangotich M, Hahn BH (1988) Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 85:602–608Google Scholar
  43. 43.
    Cronin ME, Biswas RM, Staeton C van der, Fliesher TA, Klippel JH (1988) IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated syndromes. J Rheumatol 15: 795–798Google Scholar
  44. 44.
    Alarcon-Segovia D, Deleze' M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabieides J, Fernandez L, Ponce de Leon S (1989) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective study of 500 consecutive patients. Medicine 68:353–365Google Scholar
  45. 45.
    Shergy WJ, Kredich DW, Pisetsky DS (1987) The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus. J Rheumatol 15:1389–1394Google Scholar
  46. 46.
    Montes de Oca M, Babron MC, Levy M (1990) Thrombosis and lupus anticoagulant in children with systemic lupus erythematosus. A French collaborative study (abstract). Clin Exp Rheumatol 8:216Google Scholar
  47. 47.
    Caporali R, Ravelli A, DeGennaro F, Viola S, Gentile S, Martini A, Montecucco C (1990) Anticardiolipin antibodies in childhood (abstract). Clin Exp Rheumatol 8:224Google Scholar
  48. 48.
    Watson RM, Lane AT, Barnett NK, Bias WB, Arnett FC, Provost TT (1984) Neonatal lupus erythematosus. A clinical, serological and immunogenetic study with review of the literature. Medicine 63: 362–378Google Scholar
  49. 49.
    Katayama I, Kondo S, Kanawa S, Nishioka K, Nishiyama S (1989) Neonatal lupus erythematosus with a high anticardiolipin antibody titer. J Am Acad Dermatol 21:490–492Google Scholar
  50. 50.
    Petri M, Hochberg M, Hellmann D, Corash L, Goldman D (1990) The association of the lupus anticoagulant (LA) with thrombotic events (TE) in systemic lupus erythematosus (SLE): a prospective study (abstract). Clin Exp Rheumatol 8:217Google Scholar
  51. 51.
    Frampton G, Hicks JA, Cameron JS (1990) Isotype specific antiphospholipid antibody and their clinical correlates in lupus and lupus like nephritis (abstract). Clin Exp Rheumatol 8:213Google Scholar
  52. 52.
    Petri M, Golbus M, Anderson R, Whiting O'Keefe Q, Corash LM, Hellman D (1987) Antinuclear antibody, lupus anticoagulant and anticardiolipin antibody in women with idiopathic habitual abortion. Arthritis Rheum 30:601–616Google Scholar
  53. 53.
    Out HJ, Groot PG de, Hasselaar P, Vliet M van, Derksen RHWM (1989) Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 48:1023–1028Google Scholar
  54. 54.
    Fort JG, Cowchock FS, Abruszzo JL, Smith JB (1987) Anticardiolipin antibodies in patients with rheumatic diseases. Arthritis Rheum 30:752–760Google Scholar
  55. 55.
    Asherson RA, Khamashta MA, Gil A, Vazquez J-J, Chan O, Baguley E, Hughes GRV (1989) Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease and the primary antiphospholipid syndrome. Am J Med 86: 391–399Google Scholar
  56. 56.
    Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GRV (1989) The ‘primary’ antiphospholipid syndrome: major clinical and serological features. Medicine 68:366–374Google Scholar
  57. 57.
    Coull BM, Bourdette DN, Goodnight SH Jr, Briley DP, Hart R (1987) Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke 18:1107–1112Google Scholar
  58. 58.
    Morton KE, Gavaghan TP, Krilis SA, Dagaard TP, Baron DW, Hickie JB, Chesterman CN (1986) Coronary artery bypass failure- an autoimmune phenomenon? Lancet II:1353–1357Google Scholar
  59. 59.
    Ashley S, Kruger A, McMullen KW, Darke S (1988) Prosthetic graft thrombosis associated with lupus anticoagulant. Eur J Vasc Surg 2: 57–60.Google Scholar
  60. 60.
    Hamsten A, Norberg R, Bjorkholm M, Faaire U de, Holm G (1986) Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet I: 113–116Google Scholar
  61. 61.
    Manoussakis MN, Tzioufas AG, Silis MP, Pange PJE, Goudevenos J, Moutsopoulos HM (1987) High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 69:557–565Google Scholar
  62. 62.
    Fields RA, Toubbeh H, Searles RP, Bankhurst AD (1989) The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 16: 623–625Google Scholar
  63. 63.
    Mackworth Young C, Chan J, Harris N, Walport M, Bernstein R, Batchelor R, Hughes G, Gharavi A (1987) High incidence of anticardiolipin antibodies in relatives of patients with systemic lupus erythematosus. J Rheumatol 14:723–726Google Scholar
  64. 64.
    Molta CT, Meyer O, Dosquet C, Montes de Oca M, Babron MC, Danon F, Levy M (1990) French collaborative study of childhood onset systemic lupus erythematosus: anticardiolipin antibodies in probands and first degree relatives from 37 families (abstract). Clin Exp Rheumatol 8:216Google Scholar
  65. 65.
    Elias M, Eldor A (1984) Thromboembolism in patients with the ‘lupus’-type circulating anticoagulant. Arch Intern Med 144: 510–515Google Scholar
  66. 66.
    Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJW (1985) Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol 19:265–275Google Scholar
  67. 67.
    Glueck HI, Kant KS, Weiss MA, Pollak VE, Miller MA, Coots M (1985) Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med 145: 1389–1395Google Scholar
  68. 68.
    Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR (1986) Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of the anticardiolipin antibody test. Arch Intern Med 146:2153–2156Google Scholar
  69. 69.
    Tobelem G, Carion R, Camez A (1987) The lupus anticoagulant and its role in thrombosis. Blood Rev 1:21–24Google Scholar
  70. 70.
    Chu P, Pendry K, Blevher TE (1988) Detection of lupus anticoagulant in patients attending an anticoagulation clinic. Br Med J 297: 1449Google Scholar
  71. 71.
    Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD (1989) Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 86:407–412Google Scholar
  72. 72.
    St Clair W, Rogers JS, Crough M, Hrabowsky E (1981) Deep venous thrombosis and a circulating anticoagulant in systemic lupus erythematosus. Am J Dis Child 135:230–232Google Scholar
  73. 73.
    Bernstein ML, Salusinsky-Sternbach M, Bellfleur M, Esseltine DW (1984) Thrombotic and hemorrhagic complications in children with the lupus anticoagulant. Am J Dis Child 138:1132–1135Google Scholar
  74. 74.
    Kleinknecht D, Bobrie G, Meyer O, Noel L-H, Callard P, Ramdane M (1989) Recurrent thrombosis and renal vascular disease in patients with a lupus anticoagulant. Nephrol Dial Transplant 4:854–858Google Scholar
  75. 75.
    Liano F, Mampaso F, Garcia Martin F, Pardo A, Orte L, Teruel JL, Quereda C, Ortuno J (1988) Allograft membranous glomerulonephritis and renal-vein thrombosis in a patient with a lupus anticoagulant factor. Nephrol Dial Transplant 3:684–689Google Scholar
  76. 76.
    Appan S, Boey ML, Lim KW (1987) Multiple thromboses in systemic lupus erythematosus. Arch Dis Child 62:739–741Google Scholar
  77. 77.
    Asherson RA, Khamashta MA, Baguley E, Oakley CM, Rowell NR, Hughes GRV (1989) Myocardial infarction and antiphospholipid antibodies in SLE and other disorders. Q J Med 73:1103–1115Google Scholar
  78. 78.
    Kant KS, Pollak VE, Weiss MA, Glueck HI, Miller AN, Hess EV (1982) Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine 60:71–86Google Scholar
  79. 79.
    Leaker B, Fairley KF, Dowling J, Kincaid-Smith P (1987) Lupus nephritis: clinical and pathological correlation. Q J Med 62: 163–179Google Scholar
  80. 80.
    Ponticelli C, Imbasciati E, Brancaccio D, Tarantino A, Rivolta E (1974) Acute renal failure in systemic lupus erythematosus. Br Med J 3:716–719Google Scholar
  81. 81.
    Kincaid-Smith P, Fairley KF, Kloss M (1988) Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med 69:795–815Google Scholar
  82. 82.
    Gelfand J, Truong L, Stern L, Pirani CL, Appel GB (1985) Thrombotic thrombocytopenic purpura syndrome in systemic lupus erythematosus: treatment with plasma infusion. Am J Kidney Dis 6: 154–160Google Scholar
  83. 83.
    Kincaid-Smith P, Nicholls K (1990) Renal thrombotic microvascular disease associated with lupus anticoagulant. Nephron 54:255–258Google Scholar
  84. 84.
    Derksen AHWM, Biemsma D, Bouma BN, Gmelig Meyling FHJ, Kater L (1986) Discordant effect of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum 29: 1295–1296Google Scholar
  85. 85.
    Walport MJ (1989) Pregnancy and antibodies to phospholipids. Ann Rheum Dis 48:795–797Google Scholar
  86. 86.
    Lubbe WF, Liggins GC (1985) Lupus anticoagulant and pregnancy. Am J Obstet Gynecol 153:322–327Google Scholar
  87. 87.
    Loizou S, Byron M, Englert HJ, David J, Hughes GRV, Walport MJ (1988) Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Q J Med 68:525–531Google Scholar
  88. 88.
    Unander AM, Norberg R, Hahn L, Arfors L (1987) Anticardiolipin antibodies and complement in ninety nine women with habitual abortion. Am J Obstet Gynecol 156:114–119Google Scholar
  89. 89.
    Branch DW, Scott JR, Kochenour NK, Herschgold E (1985) Obstetric complications associated with the lupus anticoagulant. N Engl J Med 313:1322–1326Google Scholar
  90. 90.
    Lockshin MD, Qamar T, Druzin ML, Goei S (1987) Antibody to cardiolipin, lupus anticoagulant, and fetal death. J Rheumatol 14: 259–262Google Scholar
  91. 91.
    Abramowsky CR, Vegas ME, Swinehart G, Byves MT (1980) Decidual vasculopathy of the placenta in lupus erythematosus. N Engl J Med 303:668–672Google Scholar
  92. 92.
    Cowchock S, Smith JB, Gocial B (1986) Antibodies to phospholipids and nuclear antigens in patients with repeated abortions. Am J Obstet Gynecol 155:1002–1010Google Scholar
  93. 93.
    Simel DL, StClair EW, Adams J, Greenberg CS (1987) Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med 83:563–566Google Scholar
  94. 94.
    Harris EN, Gharavi AE, Hegde U, Derue G, Morgan SH, Englert H, Chan JKH, Asherson RA, Hughes GRV (1985) Anticardiolipin antibodies in autoimmune thrombocytopenia. Br J Haematol 59: 231–234Google Scholar
  95. 95.
    Weinstein C, Miller MH, Axtens R, Buchanan R, Littlejohn O (1987) Livedo reticularis associated with increased titers of anticardiolipin antibody in systemic lupus erythematosus. Arch Dermatol 123:596–600Google Scholar
  96. 96.
    Englert HJ, Loizou S, Derue G, Walport M, Hughes GRV (1989) Clinical and immunologic features of livedo reticularis in lupus: a case control study. Am J Med 87:408–410Google Scholar
  97. 97.
    Bouchez B, Arnott G, Hatron PY, Wattel A, Devulder B (1985) Chorea and systemic lupus with circulating anticoagulant. Rev Neurol (Paris) 141:571–577Google Scholar
  98. 98.
    Colaco CB, Scadding GK, Lockhart S (1987) Anti cardiolipin antibodies in neurological disorders: cross reaction with anti single stranded DNA activity. Clin Exp Immunol 68:313–319Google Scholar
  99. 99.
    Harris EN, Gharavi AE, Mackworth Young CG, Patel BM, Derue G, Hughes GRV (1985) Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis 44:281–283Google Scholar
  100. 100.
    Frampton G, Winer JB, Cameron JS, Hughes RAC (1988) Severe Guillain-Barré syndrome: an association with IgA anti-cardiolipin antibody in a series of 92 patients. J Neuroimmunol 19:133–139Google Scholar
  101. 101.
    Vaarala O Palosuo T, Klemola M, Aho K (1986) Anticardiolipin response in acute infections. Clin Immunol Immunopathol 41: 8–15Google Scholar
  102. 102.
    Pankewycz OG, Migliorini P, Madaio MP (1987) Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J Immunol 139: 3287–3294Google Scholar
  103. 103.
    Mackworth-Young CG, Harris EN, Steere AC, Rizvi F, Malawista SE, Hughes GRV, Gharavi AE (1988) Anticardiolipin antibodies in Lyme disease. Arthritis Rheum 31: 1052–1056Google Scholar
  104. 104.
    Wilson WA, Perez MC, Michalski JP, Armatis PE (1987) Cardiolipin antibodies and null alleles of C4 in black Americans with systemic lupus erythematosus. J Rheumatol 15: 1768–1772Google Scholar
  105. 105.
    Inoue K, Nojima S (1969) Immunochemical studies of phospholipids IV. The reactivities of antisera against natural cardiolipin and synthetic cardiolipin-containing antigens. Chem Phys Lipids 3: 70–77Google Scholar
  106. 106.
    Harris EN, Gharavi AE, Tincani A, Chan JKH, Englert H, Mantelli P, Allegro F, Ballestrieri (sic) G, Hughes GRV (1985) Affinity purified anti cardiolipin and anti DNA antibodies. J Clin Lab Immunol 17: 155–162Google Scholar
  107. 107.
    Violi F, Valesini G, Ferro D, Tincani A, Balestrieri G, Balsano F (1986) Anticoagulant activity of anticardiolipin antibody. Thromb Res 44: 543–547Google Scholar
  108. 108.
    Pengo V, Thiagarajan P, Shapiro SS, Heine MJ (1987) Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 70: 69–76Google Scholar
  109. 109.
    McNeil HP, Chesterman CN, Krilis SA (1988) Binding specificity of lupus anticoagulants and anticardiolipin antibodies. Thromb Res 52: 609–619Google Scholar
  110. 110.
    Frampton G, Cameron JS (1988) Purified anti-phospholipid antibodies (APA) from lupus nephritis patients enhance thromboxane (TxB2) production by activated platelets (abstract). Kidney Int 33: 328Google Scholar
  111. 111.
    Guarnieri M, Eisner D (1974) A DNA antigen that reacts with antisera to cardiolipin. Biochim Biophys Acta 58: 347–353Google Scholar
  112. 112.
    Staub HL, Harris EN, Khamashta MA, Savidge G, Chahade WH, Hughes GR (1989) Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant. Ann Rheum Dis 48: 166–169Google Scholar
  113. 113.
    Lafer EM, Rauch J, Andrzejewski C Jr, Mudd D, Furie B, Furie B, Schwartz RS, Stollar B (1981) Polyspecific monoclonal lupus antibodies reactive with both polynucleotides and phospholipids. J Exp Med 153: 897–909Google Scholar
  114. 114.
    Koike T, Maruyama N, Funaki H, Tumioka H, Yoshida S (1984) Specificity of mouse hydridoma antibodies to DNA. II. Phospholipid reactivity and biological false-positive serological test for syphilis. Clin Exp Immunol 57: 347–350Google Scholar
  115. 115.
    Schoenfeld Y, Rauch J, Massicotte H, Datta S, André-Schwartz J, Stollar BD, Schwartz RS (1983) Polyspecificity of monoclonal lupus autoantibodies produced by human-human hydridomas. N Engl J Med 308: 414–420Google Scholar
  116. 116.
    Rauch J, Tannenbaum H, Stollar BD, Schwartz RS (1984) Monoclonal anticardiolipin antibodies bind to DNA. Eur J Immunol 14: 529–534Google Scholar
  117. 117.
    Carroll P, Stafford D, Schwartz RS, Stollar BD (1985) Murine monoclonal anti-DNA autoantibodies bind to endogenous bacteria. J Immunol 135: 1086–1090Google Scholar
  118. 118.
    Harris EN, Gharavi AE, Loizou S, Derue G, Chan JK, Patel BM, Mackworth-Young CG, Bunn CC, Hughes GRV (1985) Crossreactivity of antiphospholipid antibodies. J Clin Lab Immunol 16: 1–16Google Scholar
  119. 119.
    Eilat D, Zlotnick AY, Fischel R (1986) Evaluation of the cross reaction between anti-DNA and anti-cardiolipin antibodies in SLE and experimental animals. Clin Exp Immunol 65: 269–278Google Scholar
  120. 120.
    Koike T, Tomioka H, Kamagai A (1982) Antibodies cross reactive with DNA and cardiolipin in patients with systemic lupus erythematosus. Clin Exp Immunol 50: 298–302Google Scholar
  121. 121.
    Colaco CB, Elkon KB (1985) The lupus anticoagulant: a disease marker in antinuclear antibody-negative lupus that is cross reactive with autoantibodies to double stranded DNA. Arthritis Rheum 28: 67–74Google Scholar
  122. 122.
    Smeenk RJ, Lucassen WAM, Swaak TJG (1987) Is anticardiolipin activity a cross reaction of anti DNA or a separate entity? Arthritis Rheum 30:607–617Google Scholar
  123. 123.
    McNeil HP, Chesterman CN, Krilis SA (1990) Antiphospholipid antibodies are directed against a complex antigen which includes a lipid-binding glycoprotein (abstract). Clin Exp Rheumatol 8: 209Google Scholar
  124. 124.
    Galli M, Maasen C, Comfurius P, Hemker HC, Barbui T, Zwaal RFA, Bevers EM (1990) Isolation and characterisation of a plasmatic factor interacting with anticardiolipin antibodies (abstract). Clin Exp Rheumatol 8: 206Google Scholar
  125. 125.
    Yin ET, Gaston LW (1965) Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb Diath Haemorr 14: 88–115Google Scholar
  126. 126.
    Rivard GE, Schiffman S, Rapaport SI (1974) Cofactor of the “lupus anticoagulant”. Thromb Diath Haemorr 32: 554–563Google Scholar
  127. 127.
    Firkin BG, Booth P, Hendrix L, Howard MA (1978) Demonstration of a platelet bypass mechanism in the clotting system using an acquired anticoagulant. Am J Hematol 5: 81–92Google Scholar
  128. 128.
    Schick PK, Kurica KB, Chacko GK (1976) Location of phosphatidylethanolamine and phosphatidylserine in the human platelet plasma membrane. J Clin Invest 57: 1221–1226Google Scholar
  129. 129.
    Howard MA, Firkin BG (1983) Investigations of the lupus-like inhibitor bypassing activity of platelets. Thromb Haemost 50: 775–779Google Scholar
  130. 130.
    Hasselaar P, Derksen RHMW, Blokzijl L, Groot PG de (1988) Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemost 59: 80–85Google Scholar
  131. 131.
    Khamashta MA, Harris EA, Gharavi AE Derue G, Gil A, Vasquez JJ, Hughes GRV (1988) Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 47: 849–854Google Scholar
  132. 132.
    Parbtani A, Frampton G, Cameron JS (1980) Platelet and plasma serotonin concentrations in glomerulonephritis. Clin Nephrol 14: 112–123Google Scholar
  133. 133.
    Marchesi D, Parbtani A, Frampton G, Livio M, Remuzzi G, Cameron JS (1981) Thrombotic tendency in systemic lupus erythematosus (letter). Lancet I: 719Google Scholar
  134. 134.
    Frampton G, Perl S, Bennett A Cameron JS (1986) Platelet associated DNA and anti-DNA antibody in systemic lupus erythematosus with nephritis. Clin Exp Immunol 63: 621–628Google Scholar
  135. 135.
    Frampton G, Gharavi A, Harris EN, Hughes GRV, Cameron JS (1984) Platelet associated DNA, anti DNA antibody and anticardiolipin antibody in lupus nephritis (abstract). Eur J Rheumatol Inflamm 7: 19–20Google Scholar
  136. 136.
    Le Roux G, Wautier MP, Guillevin L, Wautier JL (1986) IgG binding to endothelial cells in systemic lupus erythematosus. Thromb Haemost 56: 144–146Google Scholar
  137. 137.
    Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato A, Khamashta M, Hughes GRV, Zanussi C, Balestrieri G (1988) Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 74: 247–253Google Scholar
  138. 138.
    Carreras LO, Vermylen JG (1982) ‘Lupus’ anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb Haemost 48: 28–40Google Scholar
  139. 139.
    McVerry BA, Machin SJ, Parry H, Goldstone AH (1980) Reduced prostacyclin activity in systemic lupus erythematosus. Ann Rheum Dis 39: 524–525Google Scholar
  140. 140.
    Rustin MHA, Bull HA, Dowd PM, Isenberg DA, Snaith ML, Machin SL (1987) Presence of the lupus anticoagulant in patients with systemic lupus erythematosus does not cause inhibition of prostacyclin production (abstract). Thromb Haemost 58: 390Google Scholar
  141. 141.
    Petraiuolo W, Bocill E, Hoak J (1987) The lupus anticoagulant does not inhibit the release of prostacyclin from human endothelial cells (abstract). Thromb Haemost 58: 390Google Scholar
  142. 142.
    Violi F, Valesini G, Iulano L, Ghiselli A, Falco M, Balsano F (1987) Anticardiolipin antibodies and prostacyclin synthesis (letter). Thromb Haemost 57: 374Google Scholar
  143. 143.
    Coade SB, Haaren E van, Loizou S, Walport MJ, Denman AM, Pearson JD (1989) Endothelial prostacyclin release in systemic lupus erythematosus. Thromb Haemost 61: 97–100.Google Scholar
  144. 144.
    Comp PC, De Bault LE, Esmon NL, Esmon CT (1983) Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants (abstract). Blood 62 [Suppl 1]: 299 aGoogle Scholar
  145. 145.
    Freyssinet J-M, Cazenave J-P (1987) Lupus like anticoagulants: modulation of the protein C pathway and thrombosis. Thromb Haemost 58: 679–681Google Scholar
  146. 146.
    Cariou R, Tobelem G, Soria C, Caen J (1986) Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant (letter). N Engl J Med 314: 1193–1194Google Scholar
  147. 147.
    Van Hinsberg VWM, Bertina, RM, Wijngaarden A van, Tilburg NH van, Emels JJ, Haverkate F (1985) Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 65: 444–451Google Scholar
  148. 148.
    Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ (1985) Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 82: 1121–1125Google Scholar
  149. 149.
    Angles-Cano E, Sultan Y, Clauvel J-P (1979) Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation to endothelial cell damage. J Lab Clin Med 94: 312–322Google Scholar
  150. 150.
    Byron MA, Allington MJ, Chapel HM, Mowat AG, Cederholm-Williams SA (1987) Indications of vascular endothelial dysfunction in systemic lupus erythematosus. Ann Rheum Dis 46: 741–745Google Scholar
  151. 151.
    Cosgriff TM, Martin BA (1981) Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum 24: 94–96Google Scholar
  152. 152.
    Sanfelippo MJ, Drayna CJ (1982) Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am J Clin Pathol 77: 275–279Google Scholar
  153. 153.
    De Wolf F, Carreras LO, Moerman P, Vermylen J, Assche A van, Renaer M (1982) Decidual vasculopathy and extensive placental infarction in a patient with thromboembolic recurrent fetal loss and a lupus anticoagulant. Am J Obstet Gynecol 142: 829–834Google Scholar
  154. 154.
    Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN (1985) Measurement of anticardiolipin by an enzyme linked immunoabsorbent assay (ELISA) standardization and quantitation of results. Clin Exp Immunol 54: 709–712Google Scholar
  155. 155.
    Colaco CB, Male DK (1985) Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity. Clin Exp Immunol 59: 449–456Google Scholar
  156. 156.
    Mouritsen S Hoeier-Madsen M, Wiil A, Orum O, Strandberg Petersen N (1989) The specificity of anti-cardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus. Clin Exp Immunol 76: 178–183Google Scholar
  157. 157.
    Cowchock S, Fort J, Munoz S, Norberg R, Maddrey W (1988) False positive ELISA tests for cardiolipin antibodies in sera from patients with repeated abortion, rheumatologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abortion. Clin Exp Immunol 73: 289–294Google Scholar
  158. 158.
    Harris EN, Gharavi AE, Patel SP, Hughes GR (1987) Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 215–222Google Scholar
  159. 159.
    Third International symposium on anti-phospholipid antibodies, Kingston Jamaica, January 5–8 1988. Clin Exp Rheumatol 6: 189–215Google Scholar
  160. 160.
    Triplett DA (1989) Screening for the lupus anticoagulant. Res Clin Lab 19: 379–389Google Scholar
  161. 161.
    Byron MA (1982) The clotting defect in SLE. Clin Rheum Dis 8: 137–151Google Scholar
  162. 162.
    Triplett DA, Brandt JT, Musgrave KA, Orr CA (1985) The laboratory heterogeneity of lupus anticoagulants. Arch Pathol Lab Med 109: 946–951Google Scholar
  163. 163.
    Alving BM, Barr CF, Tang DB (1990) Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med 88: 112–116Google Scholar
  164. 164.
    Triplett DA, Brandt JT, Musgrave KA, Orr CA (1988) The relationship between lupus anticoagulants and antibodies to phospholipids. JAMA 259: 550–554Google Scholar
  165. 165.
    Rosove MH, Brewer PMC, Runge A, Hirji K (1989) Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids. Am J Hematol 32: 148–149Google Scholar
  166. 166.
    Asherson RA, Chan JKH, Harris EN, Gharavi AE, Hughes GRV (1985) Anti cardiolipin antibody, recurrent thrombosis and warfarin withdrawal. Ann Rheum Dis 44:823–825Google Scholar
  167. 167.
    Schleider MA, Nachman RL, Jaffe EA, Coleman M (1976) A clinical study of the lupus anticoagulant. Blood 48: 499–509Google Scholar
  168. 168.
    Landi G, Calloni MV, Sabbadini MG (1983) Recurrent ischemic attacks in young adults with lupus anticoagulant. Stroke 14: 377–379Google Scholar
  169. 169.
    Trudinger BJ, Stewart GJ, Cook CM, Connelly A, Exner T (1988) Monitoring lupus anticoagulant-positive pregnancies with umbilical artery flow velocity waveforms. Obstet Gynecol 72: 215–218Google Scholar
  170. 170.
    Prentice RL, Gatenby PA, Loblay RH, Shearman RP, Kronenberg H, Basten A (1984) Lupus anticoagulant in pregnancy (letter). Lancet II: 464Google Scholar
  171. 171.
    Lockshin MD (1987) Anticardiolipin antibody. Arthritis Rheum 30: 471–472Google Scholar
  172. 172.
    Elder MG, Swiet M de, Robertson A, Elder MA, Flloyd E, Hawkins DF (1988) Low-dose aspirin in pregnancy (letter). Lancet I: 410Google Scholar
  173. 173.
    Ordi J, Barquinero J, Vilardell M, Jordana R, Tolosa C, Selva A, Genover E (1989) Fetal loss treatment in patients with antiphospholipid antibodies. Ann Rheum Dis 48: 798–802Google Scholar
  174. 174.
    Rosove MH, Tabsh K, Howard P, Wasserstrum N, Bronkman CR, Hahan BH, Kalunian KC (1987) Heparin therapy for prevention of fetal wastage in women with anticardiolipin antibodies and lupus anticoagulants (abstract). Blood 70 [Suppl 5]: 379aGoogle Scholar
  175. 175.
    Englert HJ, Derue GM, Loizou S, Hawkins DF, Elder MG, Swiet M de, Walport MJ, Hughes GRV (1988) Pregnancy and lupus: prognostic indicators and response to treatment. Q J Med 66: 125–136Google Scholar
  176. 176.
    Scott JR, Branch DW, Kochenour NK, Ward K (1988) Intravenous globulin treatment of pregnant patients with recurrent pregnancy loss due to antiphospholipid antibodies and Rh immunisation. Am J Obstet Gynecol 159: 1055–1056Google Scholar
  177. 177.
    Carreras LO, Perez GN, Vega HR, Casavilla F (1988) Lupus anticoagulant and recurrent fetal loss successful treatment with gammaglobulin. Lancet II: 393–394Google Scholar
  178. 178.
    Frampton G, Cameron JS, Thom M, Jones S, Raftery M (1987) Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low dose prednisolone (letter). Lancet II: 1023–1024Google Scholar
  179. 179.
    Fulcher D, Stewart G, Exner T, Trudinger B, Jeremy R (1989) Plasma exchange and the anticardiolipin syndrome in pregnancy (letter). Lancet II: 171Google Scholar
  180. 180.
    Harris EN (1988) Solid phase anti-cardiolipin test revisited. Am J Med 85: 599–600Google Scholar
  181. 181.
    Mackworth-Young CG, Loizou S, Walport MJ (1989) Antiphospholipid antibodies and disease. Q J Med 72: 767–777Google Scholar
  182. 182.
    Mackworth Young C (1989) Antiphospholipid antibodies: more than just a disease marker? Immunol Today 11: 60–65Google Scholar
  183. 183.
    Lie JT (1989) Vaculopathy in the antiphospholipid syndrome: thrombosis of vasculitis, or both? J Rheumatol 16: 713–715Google Scholar
  184. 184.
    Simon LS, Gorn AH (1990) Case no 11-1990. Case records of the Massachusetts General Hospital. N Engl J Med 322: 754–769Google Scholar

Copyright information

© IPNA 1990

Authors and Affiliations

  • J. Stewart Cameron
    • 1
  • G. Frampton
    • 1
  1. 1.Renal Unit, Clinical Science LaboratoriesGuy's HospitalLondonUK

Personalised recommendations